Eli Lilly Shares Purchased by Investment Firm

Neville Rodie & Shaw Inc. boosts stake in pharmaceutical giant

Mar. 21, 2026 at 9:58am

Got story updates? Submit your updates here. ›

Neville Rodie & Shaw Inc., an investment management firm, increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 35.7% during the fourth quarter, according to a recent SEC filing. The firm now owns 19,168 shares of the pharmaceutical company's stock, valued at approximately $20.6 million.

Why it matters

Eli Lilly is one of the world's leading pharmaceutical companies, known for its innovative drug development in areas like diabetes, obesity, and immunology. The increase in ownership by Neville Rodie & Shaw suggests the investment firm sees long-term growth potential in Lilly's pipeline and business.

The details

According to the 13F filing, Neville Rodie & Shaw purchased an additional 5,041 shares of Eli Lilly during the fourth quarter, bringing its total position to 19,168 shares. This represents a 35.7% increase in the firm's Lilly holdings compared to the prior quarter. Eli Lilly makes up 1.5% of Neville Rodie & Shaw's overall investment portfolio, making it the 19th largest holding.

  • Neville Rodie & Shaw increased its Eli Lilly position during the fourth quarter of 2025.

The players

Neville Rodie & Shaw Inc.

An investment management firm that has increased its stake in pharmaceutical company Eli Lilly and Company.

Eli Lilly and Company

A global pharmaceutical company known for its innovative drug development in areas like diabetes, obesity, and immunology.

Got photos? Submit your photos here. ›

The takeaway

The increased investment by Neville Rodie & Shaw in Eli Lilly suggests the firm sees long-term growth potential in the pharmaceutical company's pipeline and business. This reflects broader investor confidence in Lilly's ability to continue innovating and driving value for shareholders.